Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
breast cancer
AI and Machine Learning
Merck grows more ambitious about 'workhorse' TROP2 ADC
Merck has already registered 15 global phase 3 trials for its Kelun-partnered TROP2 antibody-drug conjugate, sac-TMT.
Angus Liuu
Oct 20, 2025 4:00pm
ESMO: Datroway data edge out Trodelvy in first TROP2 face-off
Oct 19, 2025 2:30am
ESMO: Enhertu wields 2-fisted power in early breast cancer
Oct 18, 2025 10:30am
ESMO: Eli Lilly looks to drive Verzenio adoption with survival win
Oct 17, 2025 8:00am
Pfizer scores again in HER2-positive breast cancer
Oct 14, 2025 12:33pm
Novartis survey explores women's feelings about breast health
Oct 7, 2025 3:30pm
